AOD-9604: Research Profile, Dosages & Supplier Prices
AOD-9604 is a metabolic research compound with a molecular weight of 1815.1 g/mol and a research half-life of short plasma half-life in published research. AOD-9604 is a modified fragment of human growth hormone (residues 177-191 with an N-terminal tyrosine) developed by an Australian company as an anti-obesity drug candidate. It progressed through human clinical trials but did not achieve approval - the full trial data is nonetheless published, which is unusual transparency for the research peptide space.
Research Use Only (RUO). Not for human or veterinary use. Not medical advice.
| Sequence | Tyr-hGH(177-191) with N-terminal Tyr addition |
| Formula | C78H123N23O23S2 |
| Mol. weight | 1815.1 g/mol |
| Half-life | Short plasma half-life in published research |
| Forms sold | Lyophilized vial, troches |
What is AOD-9604?
Published research investigated fat metabolism signaling without the growth-promoting or diabetogenic effects of full-length GH. It holds GRAS (Generally Recognized As Safe) status for certain food applications in the US.
AOD-9604 is a mid-length fragment synthesis. Quality varies mainly in purity - look for 98%+ HPLC on batch COAs.
Mechanism of Action (Research Context)
Studied for lipolysis stimulation and lipogenesis inhibition via the C-terminal GH region, without activating the full GH receptor signaling profile in research models.
Research Areas
AOD-9604 Dosages in Research
Published human trials used low milligram-range daily oral/injected dosing. Laboratory research use only.
Dosage information is a summary of published laboratory research and is provided for informational purposes only. These compounds are not for human use.
Storage & Handling
Lyophilized: -20C. Reconstituted: 2-8C, use within 30 days.
AOD-9604 Supplier Price Comparison
No tracked suppliers stock AOD-9604 yet — inventory syncs run continuously. Check our supplier reviews.